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Abstract
RNA splicing is a key mechanism linking genetic variation with psychiatric disorders. Splicing profiles are particularly
diverse in brain and difficult to accurately identify and quantify. We developed a new approach to address this challenge,
combining long-range PCR and nanopore sequencing with a novel bioinformatics pipeline. We identify the full-length
coding transcripts of CACNA1C in human brain. CACNA1C is a psychiatric risk gene that encodes the voltage-gated
calcium channel CaV1.2. We show that CACNA1C’s transcript profile is substantially more complex than appreciated,
identifying 38 novel exons and 241 novel transcripts. Importantly, many of the novel variants are abundant, and
predicted to encode channels with altered function. The splicing profile varies between brain regions, especially in
cerebellum. We demonstrate that human transcript diversity (and thereby protein isoform diversity) remains under-
characterised, and provide a feasible and cost-effective methodology to address this. A detailed understanding of isoform
diversity will be essential for the translation of psychiatric genomic findings into pathophysiological insights and novel
psychopharmacological targets.
Introduction
Genomic studies have identified numerous common single
nucleotide polymorphisms (SNPs) that are robustly asso-
ciated with psychiatric disorders; the challenge is now to
understand the underlying pathophysiological mechanisms
[1]. Most of these SNPs are non-coding [2–4], implying that
they mediate disease associations by influencing aspects of
RNA expression. Of the various mechanisms of RNA reg-
ulation, the possibility that psychiatric risk SNPs might
influence RNA splicing is particularly appealing, given its
exquisite, cell type-specific regulation and its key role in
determining neuronal properties [5]. Consistent with this
hypothesis, at a global level, cellular studies emphasise
RNA splicing as a key mechanism mediating the effect
of disease-associated, non-coding variants in complex
disorders, including schizophrenia [6]. Similarly, in human
brain, genomic regions associated with schizophrenia
are enriched for genes that show differential isoform
usage across neurodevelopment [7], implicating many
schizophrenia-associated risk loci in the regulation of the
expression of specific RNA transcripts. Consistent with
these findings, examples of associations between psychia-
tric risk-associated loci and the abundance of novel,
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alternatively spliced transcripts are beginning to emerge
[8–10], complementing numerous reports of altered splicing
patterns in the brains of psychiatric cases, compared with
controls [11–13].
Splicing varies extensively across human development
and aging [7], and between tissues. The brain exhibits one
of the highest levels of splicing diversity and prominent use
of tissue-specific exons, microexons and splicing factors
[14–18]. However, despite extensive efforts to improve the
annotation of the human genome [19], the alternative spli-
cing patterns of many genes remain poorly described,
especially in brain, and novel coding exons (many of which
are enriched within brain-expressed genes [20, 21]) and
transcripts are continually being discovered. This is due to
the limited availability of high-quality, post-mortem human
tissue and to technical limitations associated with standard
approaches: most rely on short-read RNA-Seq and the
reconstruction of fragmented sequences making the dis-
ambiguation of full-length transcripts difficult, particularly
for large and complex genes. Benchmarking studies have
shown that short-read RNA-Seq methodologies are unable
to accurately reconstruct and quantitate the majority of
transcript and protein isoforms [22, 23].
The relative lack of knowledge about the splicing of
individual human genes is typified by CACNA1C. CAC-
NA1C encodes the CaV1.2 voltage-gated calcium channel
(VGCC) alpha1 subunit and is a leading genomically
informed candidate gene for multiple psychiatric disorders
[2, 3, 24, 25]. However, it is not known how its expression
and/or splicing is altered in illness, or in association
with genetic risk for it [26]. The CACNA1C gene is large
(cDNA ~13433 nucleotides [nt], 2209 amino acids [aa])
and complex, with at least 50 annotated exons and 31
predicted transcripts (Gencode 27; Fig. 1a) [17]. Its size
and complexity make accurate transcript identification and
quantification by standard gene expression measures
extremely difficult; consequently, the true full-length
protein sequence of isoforms remains unclear. Informa-
tion on the transcript diversity of human neuronal VGCC
subunits is sparse: most studies have focused on rodents
[18], or human cardiac tissue [27, 28]; the sole study
examining VGCC splicing in human brain used a single
adult sample [29]. This information is significant, both in
terms of understanding pathophysiological mechanisms
and for the development of novel pharmacological agents,
because CACNA1C encodes multiple alternatively spliced
transcripts, which result in functionally and pharmacolo-
gically distinct channels [30, 31].
To address these unknowns, we developed a straight-
forward and cost-effective approach using a long-read
sequencing technology [32–34]. We combined long-range
RT-PCR with long-read nanopore sequencing and a
novel bioinformatics pipeline to characterise full-length
CACNA1C coding sequences (CDSs) in post-mortem
human brain. We show that the transcript structure of
human CACNA1C is substantially more complex than
currently appreciated, with numerous novel transcripts and
isoforms containing unannotated exons, novel splicing
junctions, and in-frame deletions that are predicted to alter
the protein sequence and function.
Methods
Sample preparation and sequencing
Post-mortem brain tissue from three adult donors in the
Lieber Institute for Brain Development repository was
obtained from the Maryland Medical Examiner’s Office
[35]. Subjects with evidence of neuropathology, drug use
(other than alcohol), or psychiatric illness were excluded.
Demographic information is presented in Supplementary
Table 1.
Full methodological details are presented in the
Supplementary Information. Briefly, RNA was extracted
from cerebellum, striatum, dorsolateral prefrontal cortex
[DLPFC], cingulate cortex, occipital cortex and parietal
cortex and reverse transcribed. We selected these brain
regions to investigate transcript diversity in cortical and
subcortical regions known to be transcriptionally and
functionally diverse [36] and to investigate to what extent
the CACNA1C transcript profile differs between cortical
regions. Full-length CDSs (from the first to last exon
[focussing on ‘Exon1B’ the start exon most abundant in
brain [30]]) were amplified using PCR, and barcoded and
sequenced (across two runs; six samples common to both
runs) using Oxford Nanopore Technology’s MinION.
Data analysis and code availability
Our novel data analysis pipeline is available from: https://
github.com/twrzes/TAQLoRe. 2D pass reads (i.e. those
with a q-score of ≥9) with an identified barcode were
mapped to the transcriptome (hg38, ENSEMBL v82) using
a HPC version of BLAT (pblat-cluster v0.3, available from
http://icebert.github.io/pblat-cluster/ [37]) and to the CAC-
NA1C metagene containing known exonic sequences using
GMAP version 2017–04–24 [38]. Reads mapping uniquely
to CACNA1C, and with at least 50% of their length mapped
were retained for further analysis.
To identify potential novel exons, we mined the align-
ments of the reads to the transcriptome for inserts of at least
nine nucleotides in length located at the junctions between
annotated exons. To further characterize candidate novel
exons, we mapped the corresponding reads to the genome
using LAST v926 [39]. We retained candidate exons
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located within the expected intronic sequences, and at least
six nucleotides away from existing exons. Novel exonic
sequences were subsequently introduced to the CACNA1C
metagene (concatenation of all exons) and reads were
mapped again to this new model using GMAP to enable
further characterization of alternative splicing and quanti-
fication of transcript expression.
To characterize novel exon junctions, we mapped
all the reads to the human genome (hg38) using LAST
v926 [39]. We identified all exon junctions that showed
perfect and contiguous mapping (no sequencing errors
nor insertion/deletions) of the read to the genome
and used canonical acceptor and donor splice sites.
We then used this comprehensive set of exon junctions
to correct reads with sequencing errors at mapping
breakpoints by selecting the closest canonical splice site
to the breakpoint.
To annotate transcripts that include novel exons and/or
junctions, we parsed the CIGAR string from the alignment
to the metagene, to identify the combination of exon junc-
tions supported by each read. We subsequently clustered
splicing patterns to annotate a unique set of isoforms for
CACNA1C and enable their expression quantification. We
applied a similar approach to annotate the transcripts con-
taining novel splice sites. We filtered exons and transcripts
of low abundance (i.e. supported only by one read), and
clustered transcripts together to call only their longest
possible variants.
Transcript expression both on exon and splice site levels
was quantified using the number of reads supporting the
B C
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Fig. 1 Amplicon sequencing of CACNA1C. a UCSC genome browser
screenshot of CACNA1C isoforms annotated in GENCODE V27. All
transcripts in “Basic” annotated set shown. Black arrow shows
direction of transcription. TSS transcription start site. Position of
forward and reverse long-range PCR primers in first exon and
universal portion of final exon shown. Length vs Quality of all 2D pass
reads from b Run 1 c Run 2. Most reads are the full-length CACNA1C
CDS. The presence of the 3.5 kb positive control CDS spike-in can be
seen in Run1. Visualisation limited to reads between 2 and 8 kb,
encompassing >98% of pass reads in each run
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transcript model. Reads mapping to multiple transcripts
were down-weighted according to the number of transcripts
they could be mapped to. Read counts were normalized
across libraries using the trimmed Mean of M-values
normalization method (TMM) [40]. For visualisation, all
normalized counts were log10-transformed. Expression
heatmaps and PCA plots were generated using R statistical
language [41], by heatmap3 [42] and ggplot2 libraries [43],
respectively. To normalise for the difference in sequencing
depth between samples, we downsampled all libraries to
match that with the smallest sequencing depth and recom-
puted transcript expression patterns.
Quality control
A subset of novel exons and novel exon junctions found
in CACNA1C by nanopore sequencing (Supplementary
Table 2) were confirmed by PCR targeting the novel
sequence followed by Sanger sequencing (See Supple-
mentary Information for details).
RNA extracted post-mortem shows variable degradation,
and its quality is usually assessed using the RNA integrity
number (RIN). In order to identify the minimum RIN
required for reliable amplification of the full-length CDS of
CACNA1C, RNA samples were artificially degraded (Sup-
plementary Fig. 1). CACNA1C CDS amplification in these
artificially degraded samples was assessed alongside that
from striatal RNA samples of varying RINs from three adult
donors (Supplementary Table 3).
Results
We successfully amplified and sequenced the full length
~6.5 kb CACNA1C CDS (encompassing the full intron
chain of CACNA1C) from all samples (Fig. 1a). A minimum
RIN of 6 is required, and a RIN of >7 is optimal, for
amplification of full-length CACNA1C (Supplementary
Fig. 1). Sequencing run 1 produced 112024 reads, including
52994 (47%) 2D pass reads with an identified barcode. Run
2 produced 126314 reads, including 83221 (64%) 2D pass
reads with an identified barcode (Supplementary Tables 4
and 5). Most pass reads were full length, with the updated
flowcell used in Run2 providing higher quality reads with a
lower error rate (Fig. 1). All analyses were performed using
the 2D pass barcoded reads, hereafter referred to simply as
“reads”.
Long-range amplicon sequencing reveals many
novel CACNA1C exons and isoforms
We developed a bespoke alignment and mapping pipeline
to maximise the transcript information obtained from
nanopore sequencing reads, including the identification of
novel exons, acceptor and donor splice sites, and splice
junctions (Supplementary Fig. 2). Because of CACNA1C’s
complexity, we used two complementary approaches to
identify transcripts: exon-level and splice-site-level ana-
lyses. These combined approaches identified a total of 251
unique CACNA1C transcript isoforms present in human
brain, 241 of which are novel, including the use of novel
exons, novel splice sites and junctions. The identity of these





We annotated a total of 39 potential novel exons within
the CACNA1C locus, of which 38 were identified in at
least 2 individuals or tissues and supported by at least 5
nanopore reads in each library (Fig. 2a; Supplementary
Data Table 1).
We validated four out of four of the novel exons
(selected across the range of abundance) by PCR and
Sanger sequencing by confirming the splice junctions
between the novel exon and its surrounding annotated
exons. We also discovered a fifth novel exon that was
spliced in between the targeted novel exon and the nearest
known exon. This successful validation of a selection of
novel exons provides high confidence that the novel exons
identified by nanopore sequencing are real and actively
incorporated into CACNA1C transcripts.
Integration of these 38 novel exons and the mapping of
the reads to the metagene enabled the identification of novel
and known (i.e. annotated) transcripts. Novel transcripts
incorporate novel exons, and/or novel junctions between
annotated exons and/or new combinations of known junc-
tions. To limit the impact of sequencing errors on transcript
annotations, we filtered the identified transcripts retaining
only those found in at least 2 libraries with a minimum of
24 reads in total (see Supplementary Data Files 2 and 3 for
transcript identity and abundance, respectively). We also
created a high-confidence set of transcripts with an
increased minimum threshold of 100 reads (see Supple-
mentary Data Files 4 and 5 for transcript identity and
abundance, respectively). Unless otherwise stated all ana-
lyses were performed on the high-confidence transcripts set.
We identified 90 high-confidence CACNA1C transcripts
across the 6 brain regions, including 7 previously annotated
(GENCODE v27) and 83 novel (Supplementary Fig. 3).
Seven of the novel high-confidence transcripts contained
novel exons (1.8% of high-confidence reads in total), while
the remaining 76 included previously undescribed junctions
and junction combinations.
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As expected the most highly expressed transcript was
previously annotated (ENST00000399641) and is supported
by 40.2% (23.7–50%) of reads on average. In comparison,
the most highly expressed novel transcript (CACNA1C
n2199) represents on average 7.3% (2.7–25.3%) of all reads
(Fig. 2b, c). Nine of the top ten expressed transcripts were
novel, of which eight are predicted to maintain the CAC-
NA1C reading frame, suggesting a number of these most
abundant novel transcripts encode functionally distinct
protein isoforms (Fig. 2b, c). Without any thresholding,
75.5% of all the reads supported previously unannotated
transcripts. These results suggest that novel CACNA1C
transcripts are abundantly expressed as well as highly
numerous, and that current annotations are missing many of
the most abundant CACNA1C transcripts. Without filtering,
we found evidence for the expression of only 18 of the
current set of 31 annotated transcripts (GENCODE v27).
Splice-site-level analysis
The exon-level transcript identification approach described
above provides a robust and conservative means to identify
novel exons and to characterise full-length transcript
structure. However, it is relatively insensitive to small-scale
variation (of the order of a few amino acids). Therefore, we
also implemented a splice junction-level analysis to anno-
tate novel splice sites and junctions in the CACNA1C gene
model. We used a conservative approach, which relies on
the identification of junctions supported by error-free
mapping at the junction, and the presence of canonical
splice sites. We thereby identified 497 novel splice sites, of
which 393 were supported by at least 10 reads. Compared
with previously annotated splice sites, novel donor and
acceptor splice sites are less used (Supplementary Fig. 4).
Including these splice sites, and after filtering for transcripts
supported by at least 24 reads, we identified 195 transcripts,
of which 111 are predicted to be coding (see Supplementary
Data Files 6 and 7 for transcript identity and abundance,
respectively). 28 of these were identical to transcripts
identified by the exon-level analysis. Strikingly, most of the
remainder (130) resulted from small-scale (≤15 nucleotides)
differences to our high-confidence exon-level transcripts,
demonstrating the complementarity of these approaches.
We validated the presence of specific small-scale deletions
(3 and 4 amino acid microdeletions, described below) using
Sanger sequencing.
The expression profile of CACNA1C isoforms differs
between brain regions
We examined how CACNA1C isoform expression varies
across brain regions and between individuals, focussing on
transcripts identified using the exon-level approach (similar
results were obtained using the splice-site-level transcripts
[Supplementary Fig. 4]). We downsampled all libraries to
2729 (the smallest sequencing depth) prior to normalization.
Differences between tissues is the main driver of the
observed variation in expression between transcripts. Cer-
ebellum and striatum were distinct from the four regions of
the cortex (Fig. 3a, b), but expression was similar across
200 kb hg38
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Fig. 2 a Annotation and read count for novel exonic sequences within
CACNA1C. Red arrows indicate exons that have been validated
(Supplementary Table 2). b, c Top 10 most abundant CACNA1C
isoforms identified in brain using exon-level approach. b UCSC
genome browser screenshot of top isoforms. Colours denote transcript
type. c Proportion of high-confidence transcripts reads from the ten
most abundant transcripts
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individuals, consistent with observations at the tran-
scriptome level [44]. The use of the more permissive filtered
set of transcripts for expression estimation (see Methods)
further improved the separation between regions, and
highlighted potential differences in expression between
cortical regions (Supplementary Figs. 5 and 6).
Fig. 3 Comparison of CACNA1C isoform expression between indi-
viduals and tissues. a Transcript expression levels (TPM) across tis-
sues and individuals. “One” and “Two” denote sequencing runs.
b Principal Component Analysis based on normalised transcript
expression. c Isoform switching of ENST00000399641 and
CACNA1C n2199 in cerebellum. Left panel: box plots show minimum
to maximum values with line at mean value. Right panel: the
sequences of ENST00000399641 (blue) and CACNA1C n2199
(black) differ in the sequences of their 30th exons. The detail shows
the amino acid sequences of this exon in the two transcripts
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Although we did not find any tissue-specific transcripts
amongst our set of high-confidence transcripts, we
observed a pronounced transcript expression switch in
cerebellum. Outside of the cerebellum ENST00000399641
was the dominant transcript, whilst in cerebellum,
ENST00000399641 and CACNA1C n2199 were expressed
at similar levels (Fig. 3c).
Predicted impact of novel isoforms on the CaV1.2
protein model
CACNA1C encodes the pore-forming CaV1.2 alpha1 VGCC
subunit. The calcium pore conmprises 24 transmembrane
repeats, clustered into 4 domains linked by intracellular
loops (Fig. 4a). Among the 83 novel exon-level transcripts
we identified, 51 potentially encode functional CaV1.2
channels, whilst the remainder are likely non-coding as
they contain deletions in critical membrane-spanning
regions and/or frameshifts. Notably, putatively coding iso-
forms represent 87.8% of total high-confidence reads,
demonstrating that while non-coding transcripts are
numerous, it is putatively coding transcripts that represent
the vast majority of reads (Supplementary Fig. 7).
Around half of putatively coding exon-level transcripts
(25 of 51; 26.8% of total coding reads) consist of novel
combinations of already annotated exons. The remainder
include novel exons and/or deletions (Fig. 3b). Many of the
novel splicing events are seen across multiple transcripts.
For example, five transcripts (2.8% on average, 5.2%
maximally, of total coding reads) predict CaV1.2 protein
isoforms with an in-frame deletion in the intracellular I-II
linker, and seven (6.9% on average, 11.9% maximally, of
total coding reads) contain an in-frame deletion in the IVS4-
IVS5 linker (Fig. 4a). Ten protein isoforms (12.7%, on
average, 22.3%, maximally, of total coding reads)—
including CACNA1C n1925, one of the three most abundant
transcripts—include a previously described microdeletion
in the extracellular IVS3-IVS4 linker (Fig. 4b) [33]. One
also contains a 3aa in-frame insertion in this same linker
region, highlighting this region as a ‘hotspot’ for alternative
Fig. 4 Impact of novel splicing events on the CACNA1C protein
model. a CACNA1C encodes the primary pore-forming subunit of the
CaV1.2. CaV1.2 is formed of four domains (I–IV), each comprised of
six transmembrane domains (S1–S6), which are linked by intracellular
loops. The obligate beta subunit binds to the I-II intracellular loop, as
shown. Grey boxes indicate the location of novel, in-frame insertions
and deletions, discussed in the main text. Values indicate the mean
proportion of reads containing each variant. Where variants were
identified using both analysis approaches, exon-level counts were used
to derive abundance (red text); variants identified only using the splice-
site-level approach are indicated with blue text. b Number of protein
isoforms containing three microdeletions: (i) in the I-II linker, (ii) in
the IV4–5 linker and (iii) the previously reported microdeletion in the
IV3–4 linker
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splicing, of interest given the relevance of this linker for
determining channel properties [33].
Several protein isoforms predict alternative N- and
C-termini (Fig. 4a), which are involved in coupling
CaV1.2 signalling to intracellular signalling cascades and
calcium-dependent inactivation [31, 45]. Variation in these
regions is predicted to affect a small fraction of the CaV1.2
pool, but such protein isoforms may still be of biological
significance if they show altered inactivation properties and/
or coupling to second messenger systems (Fig. 4a).
The splice-site-level analysis identified additional sites of
variation (Fig. 4). Most strikingly, 47% of transcripts
included an in-frame microdeletion of 3, 4 or 5 amino acids
in the IS5–6 linker (corresponding to amino acids D306-
E310 in Uniprot entry Q13936). The 4 amino acid micro-
deletion was previously described in heart but not brain
[29], but the 3 and 5 amino acid microdeletions are novel
(Fig. 4b). Their functional impact is unknown but the S5-S6
linker is part of the pore-forming region and these micro-
deletions fall within a region previously implicated in
determining channel conductance [46].
Discussion
We combined long-range RT-PCR with nanopore sequen-
cing in order to characterize the full coding sequence from
transcripts of CACNA1C. To our knowledge, we are the first
to have used this approach successfully in human post-
mortem tissue. The vast majority of CACNA1C transcripts
are novel, and many of these are abundant. We demonstrate
marked differences in CACNA1C transcript profiles
between brain regions, with the cerebellum in particular
showing a notable switch in isoform abundance compared
with cortex. Our results demonstrate that CACNA1C tran-
scripts are much more diverse than previously appreciated,
and emphasise the importance of studying full-length iso-
forms and of access to high-quality human brain tissue.
Despite annotations of very high quality and active
curation [19, 47], an increasing number of studies report
novel protein-coding sequences and exons in the human
genome. The rapid development of long-read sequencing
technologies opens the unique opportunity to gain an
accurate representation of transcript diversity, as each read
encompasses a full transcript. This knowledge is particu-
larly critical for genes with complex models, for example a
recent study of DSCAM, identified 18,496 transcripts out of
over 19,000 of those theoretically possible [48]. We
anticipate that long-read sequencing applications will fur-
ther help decipher transcript expression and splicing, espe-
cially for genes expressed in the brain, which exhibits
prominent use of alternative splicing and tissue-specific
exons [14–18, 49].
Our study highlights the power of long-read sequencing
for the annotation and characterisation of alternatively
spliced transcripts. We demonstrate a five-fold increase in
the number of annotated transcripts for CACNA1C, iden-
tifying novel exons and deletions within the coding
sequence, as well as novel combinations of previously
annotated exons. Because of the high quality of the
genomic assembly at the CACNA1C locus [50], the novel
exons, and splice sites we describe are unlikely to result
from mapping errors. Instead, our findings support those
from transcriptome analyses that indicate that a significant
proportion of gene isoforms in human brain remain
unannotated [51]. Supporting their potential importance, a
number of the novel transcripts are highly abundant indi-
vidually, and collectively they encompass the majority of
reads. Our finding that the vast majority of reads from
novel transcripts maintain the CACNA1C reading frame
also supports the hypothesis that these are functionally
relevant and not simply products of “noisy” splicing.
Furthermore, we identified several abundant in-frame
deletions that are present in a number of transcripts; if
translated these could dramatically impact on CaV1.2′s
function in the cell [29, 30, 52]. Notably, a number of our
novel predicted protein isoforms include alterations in
domains known to be important for determining channel
properties and coupling to second messenger systems
[29, 31, 53], thereby providing testable hypotheses as to
their predicted functional impact. Now that the transcript
structure of CACNA1C is clearer, it will also be of
interest to examine the cumulative effect of functional
variation across the CaV1.2 protein on channel function.
Conversely, we identified a relatively low number of
annotated transcripts in our dataset. This is perhaps
unsurprising, given that many of the currently annotated
transcripts are likely predictions from ESTs and incom-
plete cDNAs. Taken together, these observations demon-
strate the importance of long-read sequencing for the
accurate characterisation of transcript structure and alter-
native splicing.
The need to understand the diversity of CaV1.2 isoforms
may be of clinical and therapeutic relevance. First, char-
acterization of the complement of full-length CACNA1C
isoforms is a necessary first step towards understanding
how its transcript profile might be altered by a risk variant
or disease state. Second, calcium channel blockers, which
have CaV1.2 as one of their primary targets, are licensed for
cardiovascular indications and have possible utility as a
therapeutic strategy for psychiatric disorders [54–57]. Since
the CaV1.2 proteins that arise from CACNA1C splicing
show differential sensitivity to the existing calcium channel
blockers [52] it may be possible to selectively target
disease-relevant CACNA1C isoforms and/or those that are
differentially expressed in the brain vs. the periphery, to
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provide novel psychotropic agents that are both more potent
and are freer from peripheral side effects.
Our results indicate differences in the abundance, but not
the identity, of CACNA1C transcripts between brain
regions. Utilising our more conservative exon-level analy-
sis, in most regions there is a single major CACNA1C iso-
form, with levels of expression almost five-fold higher than
the second most highly expressed transcript. However, in
the cerebellum there is a switch in transcript abundance,
such that the two most abundant transcripts are expressed at
similar levels to one another. The consistent nature of this
switch in different individuals supports the hypothesis that
this is a regulated switch in expression. In contrast, our
analysis demonstrated only minor differences in the tran-
script profile between individuals (Fig. 3b). Given these
findings, we are therefore confident that our analysis is
likely to have identified the most common and abundant
CACNA1C transcripts present in adult human brain. How-
ever, we anticipate that the relative abundance of these
transcripts will likely differ between individuals. Our splice
site-level analysis found broadly the same results, although
there was no longer a single dominant isoform in each
region, largely due to variation in the IS5–6 linker. While
we have validated these variations, increased certainty in
their abundance and impact on overall transcript structure
will likely require further improvements in exon boundary
identification with nanopore sequencing. The details of
the CACNA1C transcript structure revealed here will facil-
itate the mining of existing large-scale RNA-Seq datasets
to investigate these differences between individuals (and
between subgroups based on e.g. genotype or disease
status).
In summary, our findings demonstrate the utility of long-
range amplicon sequencing for the identification and char-
acterisation of gene isoform profiles. More specifically, they
demonstrate that the human brain CACNA1C transcriptional
profile is substantially more complex than currently appre-
ciated. Our approach focused on annotated 5′ and 3′ ends;
thus, there is a need for further in depth investigation, e.g.
using RACE and capture sequencing. Understanding the
functional consequences of this isoform diversity will
advance our understanding of the role of VGCCs in the
human brain and their involvement in psychiatric disorders
[2–4]. Finally, some of the novel isoforms we present here
may prove novel and selective therapeutic targets for these
disorders [54].
Data availability
Nanopore sequencing reads generated and analysed in the
present study are available from ENA (PRJEB34660). Tran-
script isoforms are available as supplementary data and can be
direct visualised and downloaded via our UCSC Genome
Browser Track Hub (https://genome-euro.ucsc.edu/cgi-bin/
hgTracks?hubUrl=https://opendata.earlham.ac.uk/opendata/
data/CACNA1C_isoforms/hub.txt&genome=hg38).
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